| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Insight Molecular Diagnostics Inc.$5.08
+0.23 (+4.74%)
C 42Pipeline Score Diagnostics · Clinical
Market Cap
196.65 M
EPS
-1.48
P/E Ratio
-
Value Trade
1.40 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
32.00 K
R&D Expenses
4.95 M
Operating CF
-7.64 M
Total Assets
40.43 M
Total Liabilities
51.12 M
Equity
-10.69 M
D/E Ratio
12,345
-0.33 %
Week
66.85 %
1 Month
12.36 %
3 Month
0.5 %
6 Month
-93.47 %
5 Year
-94.7 %
All Time
Cash Data
Cash Position
28.20 M
Monthly Burn
2.55 M
Runway
9.4 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
146.57 K
52 Week Range
2.33 - 8.51
% held by Insiders
68.87 %
% held by Institutions
21.53 %
Enterprise Value
170.79 M
Total Shares
32.29 M
Short %
3.95 %
Float Shares
25.48 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Insight Molecular Diagnostics Inc.
1Total events
0Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
2026
●NDA SubmissionGraftAssureDxRegulatory Filing
De novo FDA submission for marketing authorization of GraftAssureDx kit
transplanted organ rejection monitoringsource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $581M
Pipeline ValueValuation Signal
6
Drugs Scored3.0x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankInsight Molecular Diagnostics Inc. carries a moderate pipeline score (42/100), with $5.0B risk-adjusted pipeline value, led by 99mTc-MIP-1404 in Prostate Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99mTc-MIP-1404 Small molecule | Prostate Cancer | Phase 3 | NCT01654874 | 46% | $3.1B | COMPLETED | 570 | - | - | — | - | Nov 25, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
atezolizumab | triple negative breast cancer (TNBC) | Phase 3 | 2021-09-20 | DetermaIO outperformed 80 other immune related signatures; IO score demonstrated the ability to identify those TNBC patients who benefitted the most from the addition of atezolizumab; IO score was significantly more associated with pCR in atezolizumab arm than any other immune-related signatures Read More | Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishes Read More | |
atezolizumab | triple negative breast cancer (TNBC) | Phase 3 | 2021-09-20 | DetermaIO outperformed 80 other immune related signatures; IO score demonstrated the ability to identify those TNBC patients who benefitted the most from the addition of atezolizumab; IO score was significantly more associated with pCR in atezolizumab arm than any other immune-related signatures Read More | Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishes Read More | |
atezolizumab | triple negative breast cancer (TNBC) | Phase 3 | 2021-09-20 | DetermaIO outperformed 80 other immune related signatures; IO score demonstrated the ability to identify those TNBC patients who benefitted the most from the addition of atezolizumab; IO score was significantly more associated with pCR in atezolizumab arm than any other immune-related signatures Read More | Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishes Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMDXIMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
Insight Molecular Diagnostics Inc. announced that Chief Science Officer Prof. Dr. Ekkehard Schuetz has published his 200th research paper, solidifying his status as a leading figure in laboratory diagnostics. His contributions include advancements in molecular diagnostic testing for organ rejection and the development of the GraftAssure technology. This milestone highlights both his extensive experience and the ongoing innovation at iMDx.
Read more →IMDXiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
iMDx and the American Society of Transplant Surgeons have announced the recipients of the ASTS-iMDx Health Economics Research Grant. The grant has been awarded to Dr. Kenneth Andreoni and Dr. Kenneth Chavin for their contributions to understanding health economics in transplantation. This collaboration aims to enhance research in the field.
Read more →IMDXFavorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
Insight Molecular Diagnostics Inc. announced the publication of a favorable study in Clinical Chemistry, comparing its GraftAssure test to a competing NGS assay. The study found a 99.2% agreement in assessing kidney transplant rejection risk, highlighting GraftAssure's enhanced sensitivity and potential for improved patient care. The findings support the integration of dd-cfDNA testing into clinical practice.
Read more →IMDXIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
Insight Molecular Diagnostics Inc. announced that its GraftAssure assay has been published in the American Journal of Transplantation, demonstrating superior diagnostic performance in kidney transplant rejection monitoring. The CM-Score significantly improves the positive predictive value to over 80% and retains a high negative predictive value. The company is pursuing FDA marketing authorization for its test kits to enhance local transplant center capabilities.
Read more →IMDXiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
Insight Molecular Diagnostics Inc. (IMDX) will showcase its GraftAssure technology at the American Transplant Congress in Boston. The company aims to highlight the benefits of in-house organ rejection testing and announce grant winners for research on testing economics. iMDx is seeking FDA authorization for its GraftAssureDx kit, which promises faster, more affordable testing.
Read more →IMDXIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Insight Molecular Diagnostics Inc. (IMDX) reported strong progress in Q1 2026 towards the commercialization of its GraftAssureDx kidney transplant monitoring assay. The company is engaging with major transplant centers and has received positive feedback from the FDA regarding its regulatory submission. Despite a net loss of $4.3 million, the company anticipates significant orders following FDA authorization later in 2026.
Read more →IMDX▲ +9.8%on this news
iMDx to Release First Quarter 2026 Results on May 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) will announce its first quarter 2026 financial results on May 13, 2026, after market close. A live Zoom webinar will follow at 2:00 PM PT to discuss these results and include a Q&A session. An archived replay will be available on the company's website.
Read more →IMDXInsights Into the 2026 Fallopian Tube Cancer Therapeutics Market: Targeted Treatments and Early Diagnosis Fuel Market Expansion
The global fallopian tube cancer therapeutics market is set for substantial growth, expected to rise from USD 1.95 billion in 2025 to USD 5.54 billion by 2035, reflecting a compound annual growth rate of 11%. This expansion is attributable to increased focus on targeted treatments, rising awareness of gynecological cancers, and advancements in diagnostic methods. Key market players are enhancing their positions through strategic collaborations and expanding product portfolios, despite challenges such as high costs and disparities in healthcare infrastructure that may restrict therapy access. The market features significant advancements in early diagnosis and innovation in treatment options, such as PARP inhibitors.
Read more →IMDX▲ +20.3%on this news
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
Insight Molecular Diagnostics Inc. (IMDX) announced positive real-world data for its GraftAssure assay, which will be showcased at several upcoming international conferences. The company is also hosting a fireside chat at the Needham Virtual Healthcare Conference. Despite a solid cash balance, iMDx remains pre-revenue and awaits FDA approval for its GraftAssureDx assay.
Read more →IMDX▼ -13.4%on this news· ran to -38% by day 1
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
Insight Molecular Diagnostics Inc. has submitted GraftAssureDx, the first kitted dd-cfDNA assay, for FDA review. The company reports increased interest from transplant centers, with 37 engaged in the U.S. alone. They anticipate a 150-day review process and are preparing for potential FDA queries. The assay aims to revolutionize organ rejection monitoring and management.
Read more →IMDX▲ +8.7%on this news
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
Insight Molecular Diagnostics Inc. (iMDx) will announce its fourth quarter 2025 financial results on March 26, 2026, followed by a live webinar for discussion. Additionally, CEO Josh Riggs and CFO Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, engaging in one-on-one meetings with investors.
Read more →IMDXSecond Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
Insight Molecular Diagnostics Inc. has published a new peer-reviewed study affirming the superiority of its GraftAssure assay technology in kidney transplant monitoring. The study demonstrated that the proprietary Combination Model score outperformed traditional dd-cfDNA measures, indicating its potential for better predicting transplant rejection. This research supports iMDx's commercialization strategy and aims to enhance access to organ health testing for kidney transplant patients.
Read more →IMDX▲ +10.3%on this news
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
Insight Molecular Diagnostics has completed significant milestones for its GraftAssureDx test kit, including a three-site reproducibility study and the collection of sufficient clinical samples for FDA submission. The company also received ISO 13485 certification, enabling regulatory submissions in the U.K. and E.U. The firm aims to enhance organ health testing for kidney transplant patients.
Read more →IMDX▼ -22.7%on this news
iMDx Announces $26.0 Million Registered Direct Offering
Insight Molecular Diagnostics Inc. has announced a registered direct offering of 4,525,976 shares at $5.75 per share, expected to close on February 12, 2026. The offering aims to raise approximately $26 million for general corporate purposes, particularly to expand its GraftAssure product line into heart transplant rejection testing. Bio-Rad Laboratories, a significant shareholder, is participating in the offering.
Read more →IMDX▼ -22.7%on this newsshared move
IMDX ANNOUNCES $26.0
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) announced a registered direct offering for the sale of 4,525,976 shares of its common stock at a price of $5.75 per share, expected to close on February 12, 2026. The offering aims to raise approximately $26 million to support general corporate purposes, including research and development in transplant diagnostics. The company intends to enhance its GraftAssure product line particularly focusing on heart transplant rejection testing. Street Capital Markets, LLC is acting as the sole placement agent for the offering.
Read more →IMDXIMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
Insight Molecular Diagnostics Inc. (IMDX) has expressed strong support for the STAR working group's call for decentralized organ health testing, as highlighted in a recent position paper. The company believes that providing transplant centers with access to high-quality dd-cfDNA testing will enhance patient care and create a significant market opportunity. iMDx's strategy aligns with the working group's conclusions, emphasizing the importance of onsite testing for better management of transplant patients.
Read more →IMDXiMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion
Insight Molecular Diagnostics Inc. is preparing for the U.S. commercial launch of its GraftAssureDx test kit as it nears completion of its clinical trial. The company has reported significant progress towards its FDA submission, with 95% of the work completed. iMDx aims to enhance organ health testing for kidney transplant patients, leveraging partnerships and expanding its clinical engagement.
Read more →IMDX▲ +10.7%on this news· ran to +25% by day 1
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch
Insight Molecular Diagnostics Inc. (IMDX) reported progress towards launching its GraftAssureDx molecular diagnostic test, with an expected FDA submission by year-end 2025. The company anticipates entering the market in 2026, aiming for significant growth in the transplant testing sector. Recent positive developments include CMS coverage for their assay and strong engagement from transplant centers.
Read more →IMDXiMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
Insight Molecular Diagnostics Inc. (iMDx) will report its third quarter 2025 financial results on November 10, 2025, followed by a live webinar for discussion. CEO Josh Riggs will also attend the Stephens NASH25 Conference on November 19, 2025, allowing for investor engagement. The company aims to improve patient outcomes through precision diagnostics.
Read more →IMDXiMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
Insight Molecular Diagnostics Inc. (iMDx) has appointed Steven Tahmooressi as Vice President of Marketing as it gears up for the launch of its GraftAssureDx clinical assay in 2026. With over 25 years of experience, Tahmooressi will lead marketing efforts for transplant and oncology assays. The company aims to enhance access to transplant rejection testing through its innovative products.
Read more →IMDXiMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
iMDx announced a study showing its GraftAssure assay effectively monitored a kidney transplant patient who developed lymphoma. The patient maintained stable graft function for two years without immunosuppression, suggesting an 'immune reset' due to novel CAR-T therapy. This case underscores the potential of GraftAssure in managing transplant patients amid evolving treatment protocols.
Read more →IMDX▲ +8.8%on this news
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
Insight Molecular Diagnostics Inc. (IMDX) is set to showcase its GraftAssure technology at two major conferences in Singapore and Orlando. The company will discuss the clinical applications of its transplant rejection testing and its benefits for patient monitoring. iMDx aims to submit its GraftAssureDx for FDA review by year-end, highlighting its commitment to improving kidney transplant management.
Read more →IMDXInsight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
Insight Molecular Diagnostics announced a strategic update regarding a new registry aimed at collecting real-world data on kidney transplant rejection. The company plans to enroll 5,000 patients over three years to support the clinical utility of its assay. Recent positive data has bolstered the company's confidence in its growth strategy and commercial activities.
Read more →IMDXIMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
Insight Molecular Diagnostics (IMDX) has enrolled its first patient in the GraftAssureDx clinical trial, which aims to assess a new organ transplant rejection monitoring test. The trial will involve up to 125 patients and is expected to complete by the end of the year. The company has also expanded its network of participating transplant centers from five to ten, indicating strong momentum in the study.
Read more →IMDXInsights Into the $50+ Billion Urology Care Devices & Platforms Market 2025-2030 Featuring Boston Scientific, Olympus, Medtronic, Coloplast, and BD Among Other Industry Giants
The urology care devices and platforms market is expected to grow from USD 50.59 billion in 2025 to USD 67.46 billion by 2030, driven by technological advancements and rising demand. Key product segments include diagnostics, endoscopes, and urinary catheters, with applications ranging from benign prostatic hyperplasia to kidney stone management. Increased focus on minimally invasive techniques and digital health innovations are transforming patient care. However, new tariffs on imported devices present challenges for manufacturers, necessitating adjustments in sourcing and strategy.
Read more →IMDXiMDx to Participate in NYC Investment Conferences September 8 - 11
Insight Molecular Diagnostics Inc. (iMDx) announced its participation in two upcoming investor conferences in New York City. The H.C. Wainwright 27th Annual Global Investment Conference will take place on September 8-9, 2025, featuring a company presentation and one-on-one meetings. The Lake Street Capital Markets 9th Annual Best Ideas Growth Conference is scheduled for September 11, 2025, focusing on one-on-one meetings with investors.
Read more →IMDXIMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
Insight Molecular Diagnostics Inc. (IMDX) reported positive developments in its Q2 2025 results, highlighting progress toward the launch of its GraftAssureDx transplant monitoring assay. The company aims to submit for FDA review by year-end 2025, with potential marketing as early as mid-2026. The focus remains on democratizing access to molecular diagnostics and expanding into various transplant areas.
Read more →IMDX▼ -5.8%on this news
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
Insight Molecular Diagnostics (iMDx) will announce its second quarter 2025 financial results on August 11, 2025, followed by a live webinar for discussion. The company will also participate in the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 12, 2025, where management will be available for one-on-one meetings with investors.
Read more →IMDXOncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx spo
Insight Molecular Diagnostics Inc. (iMDx), previously known as Oncocyte Corporation, has announced a name change and relocation of its headquarters from Irvine, California, to Nashville, Tennessee. This rebranding aligns with the company's strategic shift towards precision biomarker-based testing in both transplant and oncology sectors. iMDx aims to expand access to molecular diagnostic kits specifically for kidney transplant patients, targeting a significant market opportunity. The company will also reveal its new corporate identity and showcase its GraftAssureIQ program at the upcoming European Society of Organ Transplantation conference in London.
Read more →IMDXOncocyte Reports Q1 2025 Results and Business Progress Q1 2025 pharma services revenue of $2.1 million, at 62% gross margin Three of the top 10 U.S. transplant centers expected to participate in clinical trial Ten global
Oncocyte Corp. reported strong financial results for Q1 2025, generating $2.1 million in pharma services revenue, with a notable increase in gross margin to 62%. The company is advancing its clinical molecular diagnostic test kit, with support from three top U.S. transplant centers anticipated to bolster an upcoming clinical trial. In addition, plans for a company rebranding are underway to reflect a larger market opportunity as Oncocyte moves closer to the commercialization of its transplant rejection testing technology.
Read more →IMDXOncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and
Oncocyte Corp. reported a successful 2024, achieving $1.5 million in Q4 revenue and $1.9 million for the full year in pharma services. The company launched the GraftAssure RUO assay in July 2024 and secured a strategic partnership with Bio-Rad Laboratories, enhancing its funding and commercialization efforts. Key advancements include FDA engagement for a clinical trial process, which aims to establish a regulated organ transplant rejection monitoring test kit. With expanding Medicare reimbursement and growing interest from leading transplant centers, Oncocyte is poised for further growth in the transplant diagnostics market.
Read more →IMDXOncocyte Prices $29.1 Million Equity Offering Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization
Oncocyte Corp. has announced a $29.1 million equity offering to finance the development of its FDA In-Vitro Diagnostic transplant assay. The offering, priced at $2.05 per share, is backed by major shareholders including strategic partner Bio-Rad Laboratories. The funds are expected to fully support the clinical trial and commercialization of the transplant assay, which aims to enhance patient diagnosis and management in transplant centers. Oncocyte's technology is designed to deliver rapid results, potentially offering better outcomes for patients undergoing kidney transplants.
Read more →IMDXOncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed
Oncocyte Corporation has reported significant progress in its commercial launch efforts, aiming to sign 20 transplant centers by the end of 2025. The company has already secured agreements with two prominent U.S. and German transplant hospitals, contributing to its vision of tapping into a substantial global market for transplant rejection testing. With growing interest in its GraftAssure product and proactive engagement from research institutions, Oncocyte is making strides toward establishing its presence in the field. Additionally, the firm is working on obtaining regulatory approvals to commercialize its technology further.
Read more →IMDXOncocyte Announces Successful GraftAssure TM Beta Launch and Q2 2024 Results Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplan
Oncocyte Corp. has successfully launched its GraftAssureTM assay, designed for early detection of graft organ damage in kidney transplant patients. Following its beta launch in July 2024, the assay has already been implemented in major transplant centers in the U.S. and Southeast Asia. The company is leveraging partnerships, particularly with Bio-Rad Laboratories, to expand its market presence, targeting an estimated $1 billion market for its diagnostic tests. GraftAssure is expected to play a vital role in Oncocyte's strategy to capture significant market share in the transplant diagnostics sector.
Read more →IMDXOncocyte Appoints Andrea James as Chief Financial Officer
Oncocyte Corporation has appointed Andrea James as its new Chief Financial Officer, effective immediately. Ms. James brings a wealth of experience from her previous roles at Axon Enterprise and Tesla, where she was instrumental in raising significant capital and supporting corporate strategy. Oncocyte expects 2024 and 2025 to be pivotal years, as they aim to establish their diagnostic tests within the transplant community and explore opportunities in oncology. The company is optimistic about its future under James's financial leadership.
Read more →IMDXE xhibit 99.1 ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Conference Call on Wednesday
Oncocyte Corporation reported its financial results for the first quarter of 2024, revealing significant developments in their diagnostic product commercialization efforts. The company secured a $15.8 million equity private placement, which includes a strategic partnership with Bio-Rad Laboratories to aid the launch of its GraftAssure transplant rejection test. Despite these advancements, revenue fell by 41% year-over-year, reflecting challenges primarily from their Pharma Services sector. Nevertheless, Oncocyte aims to maintain a low cash burn while preparing for upcoming product shipments and regulatory milestones throughout 2024.
Read more →IMDXOncocyte and Bio-Rad Partner on Global Launch of Transplant Assay - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bi
Oncocyte Corporation has partnered with Bio-Rad Laboratories for the commercialization of the GraftAssure assay, aimed at transplant monitoring. This exclusive global distribution agreement will enhance Oncocyte's reach, with the assay expected to launch in Q2 2024. Bio-Rad will invest in this partnership and has the option for further investment upon FDA clearance. The GraftAssure assay anticipates tapping into a growing market with significant testing opportunities.
Read more →IMDXOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Oncocyte Corporation has announced a $15.8 million private placement of shares priced at $2.9164 each, intended to support corporate activities and redeem Series A Preferred Stock. The placement involves a total of 5,077,387 shares and pre-funded warrants, expected to close by April 15, 2024, pending customary conditions. The company plans to file a registration statement with the SEC for the resale of shares within 60 days of the agreement. This move is part of Oncocyte's strategy to enhance its financial position in the diagnostics market.
Read more →IMDXNOW OFFICIALLY AVAILABLE!!! We are excited to announce the official launch of #VitaGraft Kidney! Previously only available through Oncocyte's Early Access Program, VitaGraft Kidney is now broadly available to transplant
Oncocyte has officially launched the VitaGraft Kidney, making the blood-based test widely available to transplant professionals. Previously limited to an Early Access Program, this test measures donor-derived cell-free DNA concentrations post-kidney transplantation. It helps indicate potential organ damage and rejection, enhancing patient monitoring and care. The company has also updated its VitaGraft Kidney web page to support this launch.
Read more →IMDXONCOCYTE REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS -Launching First Products in 1H 2024- -Conference Call on Thursday
Oncocyte Corporation reported its financial results for the third quarter of 2023, highlighting a significant reduction in cash burn and the upcoming launch of its VitaGraft Kidney test in the first half of 2024. The company experienced an operating loss increase, while its revenue was approximately $0.4 million. Despite the financial challenges, with a positive coverage decision from CMS for their innovative test, Oncocyte is positioning for potential growth in the coming years. The conference call scheduled for November 9, 2023, will discuss these results in further detail.
Read more →IMDXONCOCYTE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Conference Call on Thursday
Oncocyte Corporation has reported its financial results for the second quarter of 2023, indicating significant progress in its transplant product development and a reduction in operating losses. The company is preparing for an early access launch of its new transplant product by the end of the year. Despite low revenues of about $0.5 million, there are optimistic developments in the clinical utilities of its existing tests and a projected decrease in average cash burn. The upcoming launch and potential coverage decisions from MolDX could be pivotal for Oncocyte's future growth.
Read more →IMDXONCOCYTE ANNOUNCES 1-for-20 reverse stock split
Oncocyte Corporation announced a 1-for-20 reverse stock split, effective July 24, 2023, aimed at regaining compliance with Nasdaq's minimum bid price requirement. Shareholders approved the split at a Special Meeting on the same day, which will reduce outstanding shares to approximately 8.2 million. The post-split common stock will trade under the existing symbol "OCX" starting July 25, 2023. The company will also adjust the conversion prices of its equity awards and other financial instruments accordingly.
Read more →IMDXONCOCYTE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS -nearing manufacturing start up of first KITTED product
Oncocyte Corporation reported its financial results for the first quarter of 2023, indicating a capital raise of $13.86 million aimed at supporting its product portfolio. The company is transitioning to a kitted product business model and has made strides in clinical studies showing the effectiveness of its diagnostic tests. However, it experienced a 50% decline in revenue compared to the same period last year. Overall, Oncocyte's focus on commercialization and strong clinical results suggests potential for future growth despite current financial challenges.
Read more →IMDXONCOCYTE REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS and PLANS TO FILE FORM 12b-25 to extend filing date of its form 10-k
Oncocyte Corporation announced preliminary financial results for the year ending December 31, 2022, reporting a decrease in revenue. The company plans to file a Form 12b-25 with the SEC to extend its deadline for the Form 10-K. CEO Joshua Riggs outlined a strategic transition from a service lab model to a product-driven revenue model, which includes the appointment of new leadership and initiatives aimed at reducing costs and enhancing product offerings. Despite the company's financial challenges, there are expectations of significant savings and potential for future growth with upcoming product developments.
Read more →IMDXOncocyte Appoints Joshua Riggs as President and Chief Executive Officer
Oncocyte Corporation has appointed Joshua Riggs as its President and Chief Executive Officer effective February 24, 2023. Riggs, who previously served as interim CEO, has initiated a restructuring process focused on product strategy and cost reduction. Supported unanimously by the Board, Riggs aims to leverage Oncocyte's distinctive technology in several high-value markets while enhancing sustainable revenue growth and shareholder value amid various operational challenges.
Read more →IMDXwere derived from the Company's historical consolidated financial statements and are being presented to give effect to the Purchase Agreement. The presentation of the unaudited pro forma financial information is prepared
Oncocyte Corporation has completed the sale of approximately 70% of its subsidiary Razor Genomics to Dragon Scientific, LLC. The transaction was formalized through a Stock Purchase Agreement, allowing Oncocyte to retain a 30% stake in Razor. Following the sale, Oncocyte has presented unaudited pro forma financial statements to illustrate the financial impact of this transaction. However, the company reported a net loss, indicating ongoing financial difficulties and uncertainties regarding future performance.
Read more →IMDXInsights on the Molecular Diagnostics for Infectious Disease Global Market to 2026 - Aging Population a Boon for All Diagnostics
The 'Molecular Diagnostics for Infectious Disease' report indicates a strong growth trajectory for the diagnostics sector, propelled by COVID-19 demand and advances in multiplex testing. The report emphasizes significant opportunities arising from biotechnology innovation, particularly in rapid testing and genomics. With a comprehensive analysis, it outlines market dynamics across various countries and diseases, forecasting continued expansion over the next five years with detailed insights available for stakeholders. It aims to inform executives and advisors on strategic decisions in the clinical diagnostics field.
Read more →IMDXOncocyte Announces Initiatives to Focus Corporate Strategy
Announces Initiatives to Focus Corporate Strategy Calif., December 16, 2022 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte's workforce to realign its team towards key
Read more →IMDXOncocyte Reports Third Quarter 2022 Financial Results Irvine, Calif.
Reports Third Quarter 2022 Financial Results Calif., November 10, 2022 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient car
Read more →IMDXOncocyte Reports Second Quarter 2022 Financial Results Irvine, Calif.
Reports Second Quarter 2022 Financial Results Calif., August 10, 2022 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care
Read more →IMDXOncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective
Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by
Read more →IMDXOncocyte Reports First Quarter 2022 Financial Results Irvine, Calif.
Reports First Quarter 2022 Financial Results Calif., May 11, 2022 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care jou
Read more →IMDXONCOCYTE
CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Calif., April 13, 2022 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX), ("Oncocyte" or the "Company"), announced today that it has commenced an underwritten public offering of shares of its common
Read more →IMDXOncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock Irvine, Calif. - (GLOBE NEWSWIRE)
Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock Calif. - (GLOBE NEWSWIRE) April 13, 2022- Oncocyte Corporation (Nasdaq: OCX), ("Oncocyte" or the "Company"), a precision diagnostics company with the mission to
Read more →IMDXOncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update DetermaRx Revenues and Test Volume Grew 104% and 54%, respectively, in Q4 versus Q3 2021 Development and Co-Marketing Agr
Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Revenues and Test Volume Grew 104% and 54%, respectively, in Q4 versus Q3 2021 and Co-Marketing Agreement with Thermo Fisher Scientific to Provide Platform and Channel Partner for Deliveri
Read more →IMDXNews Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology Collaboration extends global reach for Thermo Fisher's rapid next-generation sequencing
Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology extends global reach for Thermo Fisher's rapid next-generation sequencing technology Calif., January 18, 2022 - Oncocyte Corporation (Nasdaq: OCX), a precision
Read more →IMDXOncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China Companies complete second and most critical of three steps in Technology Transfer Oncocyte receive
and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution complete second and most critical of three steps in Technology Transfer receives $2M milestone payment Calif., December 8, 2021 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnost
Read more →IMDXInsights on the Molecular Diagnostics Global Market to 2031 - Focus on Product, Testing Location, Application, Technology, and End-user
Dublin, Dec. 02, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
Read more →IMDXOncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor m
Reports Third Quarter 2021 Financial Results and Provides Corporate Update launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other biomarkers
Read more →IMDXOncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical
Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment clinical studies to date across multiple tissue types, DetermaIO has consistently proven
Read more →IMDXOncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection U.S. patent builds upon prior EU patent protection enabling
Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europ
Read more →IMDXOncocyte Appoints Gisela A. Paulsen as Chief Operating Officer Irvine, Calif.
Appoints Gisela A. Paulsen as Chief Operating Officer Calif., October 7, 2021 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diag
Read more →IMDXOncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishes
Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Test at the European Society for Medical Oncology Annual Meeting clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a biomarker of immunotherapy response Investigators found DetermaIO out
Read more →IMDXOncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update DetermaRx Q2 Sample Volume Grows 23% over Q1 2021 Potential pan-cancer utility of DetermaIO strengthened by data in breast, lung, bladd
Reports Second Quarter 2021 Financial Results and Provides Corporate Update Q2 Sample Volume Grows 23% over Q1 2021 pan-cancer utility of DetermaIO strengthened by data in breast, lung, bladder and renal cell cancer, validating the test in all four tumor types evaluated; upcom
Read more →IMDXOncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update -Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - -Data in four indications (TNBC,
Reports First Quarter 2021 Financial Results and Provides Corporate Update Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - in four indications (TNBC, NSCLC, bladder, and renal cell cancer) suggest pan-cancer utility of DetermaIO for
Read more →IMDXOncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc. Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant re
Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc. gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample technologies may provide
Read more →IMDXOncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to
Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 track to launch DetermaIO in 2021 for immune therapy selection to present dat
Read more →IMDXOncocyte to Begin Trading on the Nasdaq Stock Market on
to Begin Trading on the Nasdaq Stock Market on March 8, 2021 Calif., Feb. 23, 2021 - Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has been ap
Read more →IMDXOncocyte Announces Pricing of $35 Million Public Offering of Common Stock Irvine, Calif.
Announces Pricing of $35 Million Public Offering of Common Stock Calif., February 5, 2021 - Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, toda
Read more →IMDXOncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc. Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing Novel, patente
Announces Definitive Agreement to Acquire Chronix Biomedical, Inc. includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing patented copy number index (CNI) therapy monitoring test developed by Chronix complements Onc
Read more →IMDXOncocyte Announces $25 Million Registered Offering Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support On
Announces $25 Million Registered Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum Calif.,
Read more →IMDXONCOCYTE REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE DetermaRx receives final CMS pricing and records first full quarter with Medicare revenues; more than doubles second quarter volumes wit
REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND receives final CMS pricing and records first full quarter with Medicare revenues; more than doubles second quarter volumes with adoption at NCCN and NCI designated cancer centers selected for use in checkpoint inhibitor clinical
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Secured National Medicare Reimbursement for DetermaRx Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healt
PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS National Medicare Reimbursement for DetermaRx Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare Solutions Distribution with ProGenetics Expands Global Availability
Read more →IMDXInsights on the Worldwide Molecular Point of Care Diagnostics Industry to 2028 - Innovations in the Market Present Opportunities
Dublin, May 28, 2020 (GLOBE NEWSWIRE) -- The "Global Molecular Point of Care Diagnostics Market 2019-2028" report has been added to ResearchAndMarkets.com's offering. According to this report the global molecular point of care diagnostics market is estimated to grow with a CAGR
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Announced Final Medicare LCD from Palmetto for DetermaRx , Potentially Establishing Medicare Coverage for up to 70% of Eligible Early-St
PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Final Medicare LCD from Palmetto for DetermaRx , Potentially Establishing Medicare Coverage for up to 70% of Eligible Early-Stage First Strategic International Collaboration for DetermaRx with CORE, a Le
Read more →IMDXOncocyte Announces $10.7 Million Registered Offering Further strengthens balance sheet to support ongoing commercial and development activities
Announces $10.7 Million Registered Offering strengthens balance sheet to support ongoing commercial and development activities Calif., April 24, 2020 -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at c
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Initiated Commercial Launch of DetermaRxTM in U.S. Completed Acquisition of Insight Genetics Initiated Research Use Launc
PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Commercial Launch of DetermaRxTM in U.S. Acquisition of Insight Genetics Research Use Launch of DetermaIOTM After Completion of CLIA Validation Completion of DetermaDxTM CLIA Validation
Read more →IMDXOncocyte Closes Merger Agreement to Acquire Insight Genetics Acquisition broadens suite of molecular diagnostic tests to include potentially transformative immunotherapy response prediction test demonstrated to outperfor
Closes Merger Agreement to Acquire Insight Genetics broadens suite of molecular diagnostic tests to include potentially transformative immunotherapy response prediction test demonstrated to outperform PD-L1 and TMB significant pharma services opportunity including immunotherap
Read more →IMDXONCOCYTE ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE INSIGHT GENETICS Acquisition includes a potentially transformative immuno-oncology diagnostic test for the selection of therapy for cancer patients Data presented at SIT
ONCOCYTE ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE INSIGHT GENETICS Acquisition includes a potentially transformative immuno-oncology diagnostic test for the selection of therapy for cancer patients SITC 2019 demonstrated performance surpassing current predictive companion t
Read more →IMDXOncoCyte Announces $7.6 Million Registered Offering Proceeds strengthen balance sheet to support 2020 commercial launch and development activities
Announces $7.6 Million Registered Offering strengthen balance sheet to support 2020 commercial launch and development activities Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) - OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide action
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS DetermaVu CLIA Validation Remains On-Track for Q1 2020 Completion Acquisition of Razor Genomics Lung Cancer Treatment Stratification Tes
PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS CLIA Validation Remains On-Track for Q1 2020 Completion of Razor Genomics Lung Cancer Treatment Stratification Test with Proposed CMS Positive Coverage Decision Treatment Stratification Test Commercial
Read more →IMDXONCOCYTE CLOSES INITIAL INVESTMENT IN RAZOR GENOMICS AND ACQUIRES RIGHTS TO COMMERCIALIZE RAZOR LUNG CANCER TREATMENT STRATIFICATION TEST Transaction broadens OncoCyte's molecular diagnostic capabilities in early stage l
CLOSES INITIAL INVESTMENT IN RAZOR GENOMICS AND ACQUIRES RIGHTS TO COMMERCIALIZE RAZOR LUNG CANCER TREATMENT STRATIFICATION TEST broadens OncoCyte's molecular diagnostic capabilities in early stage lung cancer positive coverage recommendation received from the Centers for Medic
Read more →IMDXONCOCYTE ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE RAZOR GENOMICS Acquisition of Razor's treatment stratification test will broaden OncoCyte's capabilities to include the management of early-stage lung cancer In a publis
ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE RAZOR GENOMICS of Razor's treatment stratification test will broaden OncoCyte's capabilities to include the management of early-stage a published study of individuals identified as high risk by the Razor test and treated with chemothera
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS Molecular Diagnostics industry veteran Ron A. Andrews appointed CEO Melinda Griffith elected to Board of Directors Strengthened Clinica
PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS Diagnostics industry veteran Ron A. Andrews appointed CEO Griffith elected to Board of Directors Strengthened Clinical Operations and Commercial Marketing teams with key management appointments call t
Read more →IMDXAMENDMENT TO ONCOCYTE CORPORATION 2018 EQUITY INCENTIVE PLAN Approved by Shareholders
EQUITY INCENTIVE PLAN by Shareholders July 17, 2019 4.1 of the OncoCyte Corporation 2018 Equity Incentive Plan is amended to read as follows: Subject to adjustment in accordance with Section 11, a total of 11,000,000 shares of Common Stock shall be available for the grant of
Read more →IMDXONCOCYTE ANNOUNCES CHIEF EXECUTIVE OFFICER TRANSITION Appoints diagnostic industry veteran and current Board member Ronald Andrews, Jr. as Chief Executive Officer Outgoing CEO William Annett to serve as an advisor to the
ANNOUNCES CHIEF EXECUTIVE OFFICER TRANSITION diagnostic industry veteran and current Board member Andrews, Jr. as Chief Executive Officer CEO William Annett to serve as an advisor to the Company to host conference call and webcast today, June 6, at 8:30am EDT Calif., June 6,
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS Completes successful Analytical Validation study and initiates CLIA Validation study On track for commercial availability of DetermaVu i
PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS successful Analytical Validation study and initiates CLIA Validation study track for commercial availability of DetermaVu in 2H 2019 Call Today at 4:30 PM EDT Calif., May 14, 2019 - OncoCyte Corporatio
Read more →IMDXONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS On track for commercial availability of DetermaVu in 2H 2019 Conference Call Today at 4:30
PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS track for commercial availability of DetermaVu in 2H 2019 Call Today at 4:30 PM EDT Calif., April 1, 2019 - OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive t
Read more →IMDXOncoCyte Announces Proposed Public Offering of Common Stock
Announces Proposed Public Offering of Common Stock Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) - OncoCyte Corporation (NYSE American: OCX) ("OncoCyte"), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that it intends to offer
Read more →IMDXOncoCyte Announces Successful Results of DetermaVu R&D Validation Study Results show 90% sensitivity and 75% specificity, demonstrating best-in-class performance On track for commercial availability of DetermaVu Lung in
Announces Successful Results of DetermaVu R&D Validation Study show 90% sensitivity and 75% specificity, demonstrating best-in-class performance track for commercial availability of DetermaVu Lung in 2H 2019 suggest the potential to address a U.S. market opportunity of $4.7 bi
Read more →IMDXInsight Genetics Launches First-of-its-kind Test for Triple Negative Breast Cancer
NASHVILLE, Tenn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Insight Genetics, Inc. today announced the launch of its proprietary Insight TNBCtype™, a new test for categorizing triple negative breast cancer (TNBC) tumors into distinct molecular subtypes through its wholly owned CLIA- and
Read more →IMDXONCOCYTE REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROGRESS IN DETERMAVU DEVELOPMENT Transition to New Diagnostic Testing Platform Complete Prospective R&D Validation Study Results Expected by Late 2018 or Early 2
REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND IN DETERMAVU DEVELOPMENT to New Diagnostic Testing Platform Complete R&D Validation Study Results Expected by Late 2018 or Early 2019 Plan Remains On-Track, Targeting Commercial Availability in 2H 2019 Call Today at 4:30 pm ET
Read more →IMDXOncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu Development Studies Initiates Algorithm Development Study to Establish Accuracy in Interpreting Assay Results On-Track f
Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu Development Studies Algorithm Development Study to Establish Accuracy in Interpreting Assay Results for Pivotal R&D Validation Study Results by Approximately Year End, with Commercial A
Read more →IMDXEQUITY INCENTIVE PLAN ONCOCYTE CORPORATION 1. Purpose; Eligibility . 1.1 General Purpose . The name of this plan is the OncoCyte Corporation 2018 Equity Incentive Plan (the " Plan "). The purposes of the Plan are to (a)
2018 EQUITY INCENTIVE PLAN ONCOCYTE CORPORATION Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the OncoCyte Corporation 2018 Equity Incentive Plan (the "Plan"). The purposes of the Plan are to (a) enable the Company, to attract and retain the types of Em
Read more →IMDXOncoCyte Reports Second Quarter 2018 Financial Results and Positive Corporate Developments -Encouraging Study Data Drives Continued Development of DetermaVu Lung Cancer Diagnostic Test- -Conference Call Today at 4:30 pm
Reports Second Quarter 2018 Financial Results and Positive Corporate Developments Study Data Drives Continued Development of DetermaVu Lung Cancer Diagnostic Test- Call Today at 4:30 pm ET- Calif., August 14, 2018 - OncoCyte Corporation (NYSE American: OCX), a developer of nov
Read more →IMDXSeasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte
Healthcare Executive Albert P. Parker Appointed Operating Officer of OncoCyte Calif., August 9, 2018 - OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the appointment of Albert
Read more →IMDXOncoCyte Announces At Market $3.59 Million Offering of Common Stock and Warrants Alameda, California
Announces At Market $3.59 Million Offering of Common Stock and Warrants California, July 27, 2018 - OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has entere
Read more →IMDXOncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test - Results suggest improved performance of next-generation test - Study results support move to new diagnostic testing platform - Significant devel
Reports Encouraging New Study Results for Lung Cancer Blood Test Results suggest improved performance of next-generation test Study results support move to new diagnostic testing platform Significant development work required to fully validate this recent progress Calif., Jul
Read more →IMDXOncoCyte Reports First Quarter 2018 Financial Results Conference Call Today at 4:30 pm
Reports First Quarter 2018 Financial Results Call Today at 4:30 pm ET Calif., May 15, 2018 (GLOBE NEWSWIRE) - OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial and operating results fo
Read more →IMDXOncoCyte Reports Fourth Quarter and Full Year 2017 Financial Results Development of DetermaVu Remains on Track for Completion in 2018 -Conference Call Today at 4:30 pm ET
Reports Fourth Quarter and Full Year 2017 Financial Results of DetermaVu Remains on Track for Completion in 2018 Call Today at 4:30 pm ET- Calif., April 2, 2018 - OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early d
Read more →IMDXOncoCyte Announces the Closing of a $10 Million Private Placement of Common Stock Alameda, California
Announces the Closing of a $10 Million Private Placement of Common Stock California, March 28, 2018 - OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has clos
Read more →IMDXOncoCyte Announces Initial Results of DetermaVu Feasibility on New Platforms; Enhancements May Increase Lung Cancer Diagnostic Test's Clinical Performance Company Anticipates Commercial Launch During 2018 Alameda, Calif.
Announces Initial Results of DetermaVu Feasibility on New Platforms; Enhancements May Increase Lung Cancer Diagnostic Test's Clinical Performance Anticipates Commercial Launch During 2018 Calif. - March 8, 2018 - OncoCyte Corporation (NYSE American: OCX), a developer of novel,
Read more →IMDXOncoCyte Initiates Search for New Independent Director
Initiates Search for New Independent Director Calif., November 29, 2017 - OncoCyte Corporation (NYSE AMERICAN: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that it has initiated a search for a new independent member of its Bo
Read more →IMDXSeasoned Financial Executive Joins OncoCyte as Chief Financial Officer
Financial Executive Joins OncoCyte as Chief Financial Officer Calif., November 15, 2017 - OncoCyte Corporation (NYSE AMERICAN: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that Mitch Levine has been appointed Chief Financial
Read more →IMDXOncoCyte Reports Third Quarter 2017 Financial Results -Conference Call Today at 4:30 pm ET
Reports Third Quarter 2017 Financial Results Call Today at 4:30 pm ET- Calif., November 14, 2017 - OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial results for the quarter ended Sept
Read more →IMDXOncoCyte Confirms Launch Plans for Lung Cancer Diagnostic Test; Reports Progress Toward CLIA Lab Licensing and Second Quarter 2017 Financial Results - Introduces Lung Cancer Diagnostic Branding- -Conference Call Today at
Confirms Launch Plans for Lung Cancer Diagnostic Test; Reports Progress Toward CLIA Lab Licensing and Second Quarter 2017 Financial Introduces Lung Cancer Diagnostic Branding- Call Today at 4:30 pm ET- Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) - OncoCyte Corporation (NYSE MKT: OC
Read more →IMDXOncoCyte Receives $5.74 Million in Proceeds from Exercise of Warrants Alameda, California
OncoCyte Receives $5.74 Million in Proceeds from Exercise of Warrants Alameda, California - July 25, 2017 - OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $5.74 million through t
Read more →IMDXOncoCyte Continues to Make Progress Towards Commercialization; Reports First Quarter 2017 Results Expects to Report Results of 300 Patient R&D Validation Study on
OncoCyte Continues to Make Progress Towards Commercialization; Reports First Quarter 2017 Results Expects to Report Results of 300 Patient R&D Validation Study on May 22, 2017 Conference Call Scheduled for May 22, 2017 at 4:30pm ET ALAMEDA, Calif., April 28, 2017 -- OncoCyte C
Read more →IMDXOncoCyte Reports Successful Results of Lung Cancer Diagnostic Test Study; Targets 2017 Product Launch to Address $4 Billion-plus Market Data from the Study Exceed Levels Believed Necessary for a Commercially Successful T
OncoCyte Reports Successful Results of Lung Cancer Diagnostic Test Study; Targets 2017 Product Launch to Address $4 Billion-plus Market Data from the Study Exceed Levels Believed Necessary for a Commercially Successful Test Conference Call Scheduled for Today at 4:30 PM ET Al
Read more →IMDXOncoCyte Corporation Reports Fourth Quarter and Full Year 2016 Financial Results Enters into New Credit Facility with Silicon Valley Bank Conference Call Scheduled for Monday
OncoCyte Corporation Reports Fourth Quarter and Full Year 2016 Financial Results Enters into New Credit Facility with Silicon Valley Bank Conference Call Scheduled for Monday, March 6, 2017 at 4:30 PM ET Alameda, CA - (February 27, 2017) - OncoCyte Corporation (NYSE MKT:OCX),
Read more →IMDXOncoCyte Receives $2 Million in Proceeds from Early Exercise of Warrants Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test Alameda, California - (
OncoCyte Receives $2 Million in Proceeds from Early Exercise of Warrants Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test Alameda, California - (February 21, 2017) - OncoCyte Corporation (NYSE MKT: OCX), a developer of nove
Read more →IMDXOncoCyte Reports Third Quarter 2016 Financial Results Currently Processing Samples and Analyzing Results in its Lung Cancer Test Study; Continues to Project a Completion Date in Late December Conference Call to Discuss t
OncoCyte Reports Third Quarter 2016 Financial Results Currently Processing Samples and Analyzing Results in its Lung Cancer Test Study; Continues to Project a Completion Date in Late December Conference Call to Discuss the Results at 5:00 p.m. ET ALAMEDA, Calif., Nov. 10, 2016
Read more →IMDXLiquid Biopsies Next Generation Cancer Molecular Diagnostics William AnnettChief Executive OfficerSeptember 2016 Forward Looking Statements Statements pertaining to future financial and/or operating results, future resea
Liquid Biopsies Next Generation Cancer Molecular Diagnostics William AnnettChief Executive OfficerSeptember 2016 Forward Looking Statements Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology under development, cli
Read more →IMDXDon M. Bailey Appointed to OncoCyte Corporation's Board of Directors Experienced Senior Executive with Track Record of Consistently and Rapidly Building Shareholder Value at Several Companies Makes Equity Investment in O
Don M. Bailey Appointed to OncoCyte Corporation's Board of Directors Experienced Senior Executive with Track Record of Consistently and Rapidly Building Shareholder Value at Several Companies Makes Equity Investment in OncoCyte ALAMEDA, Calif., Aug. 29, 2016 (GLOBE NEWSWIRE) -
Read more →IMDXOncoCyte Corporation Announces the Closing of Two Private Placement Transactions Generating Gross Proceeds of $10.55 Million Net Proceeds to be Used to Continue R&D of Non-Invasive Cancer Diagnostics Tests and CLIA Compl
OncoCyte Corporation Announces the Closing of Two Private Placement Transactions Generating Gross Proceeds of $10.55 Million Net Proceeds to be Used to Continue R&D of Non-Invasive Cancer Diagnostics Tests and CLIA Compliant Laboratory Build-Out Alameda, CA - August 29, 2016 -
Read more →IMDXOncoCyte Reports Second Quarter 2016 Financial Results Conference Call to Discuss the Results at 5:00 p.m.
OncoCyte Reports Second Quarter 2016 Financial Results Conference Call to Discuss the Results at 5:00 p.m. ET ALAMEDA, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) - OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive blood based tests for the early detection of
Read more →IMDXOncoCyte Reports First Quarter 2016 Financial Results Conference Call to Discuss the Results at 5 p.m.
OncoCyte Reports First Quarter 2016 Financial Results Conference Call to Discuss the Results at 5 p.m. ET ALAMEDA, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive blood based tests for the early detection of canc
Read more →IMDXOncoCyte Corporation Reports Full Year 2015 Financial Results Alameda, CA - (
OncoCyte Corporation Reports Full Year 2015 Financial Results Alameda, CA - (March 30, 2016) - OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, reported its financial results for the year ended December
Read more →IMDXOncoCyte Corporation and The Wistar Institute Enter into Global Licensing Agreement Exclusive Rights to Commercialize Biomarker Assay Follows Years of Positive Collaboration on Lung Cancer Diagnostic Test ALAMEDA, Calif.
OncoCyte Corporation and The Wistar Institute Enter into Global Licensing Agreement Exclusive Rights to Commercialize Biomarker Assay Follows Years of Positive Collaboration on Lung Cancer Diagnostic Test ALAMEDA, Calif. and PHILADELPHIA, Jan. 27, 2016 (GLOBE NEWSWIRE) -- OncoC
Read more →IMDXOncoCyte Corporation Initiates Trading on the NYSE MKT Company's Common Stock Listed Under the Symbol "OCX" beginning
OncoCyte Corporation Initiates Trading on the NYSE MKT Company's Common Stock Listed Under the Symbol "OCX" beginning January 4, 2016 The Company Will Publish an Introductory Investor Webcast January 5, 2016 at 4 p.m. ET OncoCyte Scheduled to Ring the NYSE Opening Bell on Wedn
Read more →Competitive Position
How IMDX ranks across every disease it competes inCompetitive Position is a premium feature
See how IMDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial